Amplyx Pharmaceuticals often referred to as simply Amplyx, is a San Diego-based company that develops advanced therapeutic solutions for life-threatening fungal infections.
The company has created several new classes of medicines to treat fungal infections that do not respond to other types of medication.
In October 2015, the company received $50 million in Series B funding for Phase 2 development of these drugs.
LeMasters stated ” “The emerging COVID-19 pandemic has provided a reminder of the critical threat of opportunistic microbial infections in patients who have become immunocompromised,” said LeMasters. “There is a dire need for novel and effective treatments, both for these superinfections as well as infections impacting patients whose immune systems are compromised through other means, like anti-cancer therapies.”
Amplyx maintains a corporate office in San Diego, California.